|
CN111617255A
|
|
Combination therapy for treating central nervous system disorders
|
|
WO2020088459A1
|
|
Novel rationally designed protein compositions
|
|
WO2020074010A1
|
|
New combination solution for treating chemotherapy refractory cancer
|
|
CA3113016A1
|
|
Treatment for non-alcoholic fatty liver disease
|
|
TW202034911A
|
|
Treatment for obesity
|
|
AU2019324388A1
|
|
Novel cancer immunotherapy antibody compositions
|
|
WO2019047866A1
|
|
Novel therapeutics for central nervous system disorders
|
|
KR20170089003A
|
|
Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
|
|
CN106132412A
|
|
The new method for the treatment of cancer
|
|
KR20160105882A
|
|
Novel synthetic biology-based adcc technology
|
|
EP3295796A1
|
|
Novel compounds and compositions for targeting cancer stem cells
|
